Related Experiment Videos
Intraperitoneal erythropoietin in children on peritoneal dialysis: A study of pharmacokinetics and efficacy
A T Kausz1, S L Watkins, C Hansen
1Division of Nephrology, University of Washington, Children's Hospital, Seattle, WA, USA.
Insights
Intraperitoneal recombinant human erythropoietin (rHuEPO) is effective for children on peritoneal dialysis, showing similar bioavailability to subcutaneous dosing. Further research is needed to assess the potential increased risk of peritonitis.
Area of Science:
- Pediatric Nephrology
- Pharmacokinetics
- Renal Replacement Therapy
Background:
- Children with chronic kidney disease often require erythropoiesis-stimulating agents.
- Peritoneal dialysis (PD) is a common treatment for pediatric end-stage renal disease.
- Alternative administration routes for recombinant human erythropoietin (rHuEPO) are explored to improve patient convenience and outcomes.
Purpose of the Study:
- To evaluate the pharmacokinetics and efficacy of intraperitoneal (IP) rHuEPO in children undergoing chronic peritoneal dialysis.
- To compare the bioavailability of IP rHuEPO with traditional subcutaneous (SC) administration.
- To assess the safety and effectiveness of long-term IP rHuEPO therapy in this population.
Main Methods:
- A single IP dose of rHuEPO was administered to eight children on PD, with serum EPO levels monitored over 24 hours.
- Nine children received 11-12 weeks of chronic IP rHuEPO therapy.
- Hematocrit levels and rHuEPO dosages were compared to previous SC treatment, and peritonitis risk was assessed.
Main Results:
- A mean peak serum erythropoietin (EPO) level of 187 mU/mL was achieved at 12 hours post-IP administration.
- The relative bioavailability of IP rHuEPO was comparable to SC dosing.
- Patients maintained normal hematocrit levels with similar rHuEPO dosages, but a trend towards increased peritonitis risk was observed.
Conclusions:
- Intraperitoneal rHuEPO is an effective treatment for anemic children on continuous cycling peritoneal dialysis.
- The required rHuEPO dosage for IP administration is not significantly different from SC dosing.
- The potential for an increased risk of peritonitis with IP rHuEPO warrants further investigation.
Abstract:
The pharmacokinetics and efficacy of intraperitoneal (IP) recombinant human erythropoietin (rHuEPO) were investigated in children undergoing chronic peritoneal dialysis. Eight children were administered a single dose of 100 U/kg of rHuEPO IP with 50 mL of dialysate into a dry peritoneal cavity after nighttime peritoneal dialysis. Serum erythropoietin (EPO) levels were measured at 0, 8, 12, and 24 hours. A mean peak EPO level of 187 mU/mL was obtained at 12 hours. The area under the curve was 5,818 mU/h/mL, and relative bioavailability was similar to that found using subcutaneous (SC) dosing. Nine children completed 11 to 12 weeks of IP rHuEPO therapy. The patients maintained a normal hematocrit (34% +/- 2.3%) with a mean final IP rHuEPO dosage that was not significantly greater than the mean previous SC dosage (IP, 290 +/- 194 U/kg/wk; SC, 279 +/- 126 U/kg/wk; P = not significant). There appeared to be a trend for a slightly increased risk for peritonitis compared with historical controls at our center (relative risk = 3.1; 95% confidence interval, 0.92 to 6.3). IP rHuEPO is effective in children undergoing continuous cycling peritoneal dialysis without requiring increased rHuEPO dosages, but the possibility of an increased risk for peritonitis will need to be further explored.